Polymorphism ofXRCC1,XRCC3, andXPDGenes and Risk of Chronic Myeloid Leukemia

Abstract

The genetic polymorphisms of X-ray repair cross complementing group 1 (XRCC1), X-ray repair cross complementing group 3 (XRCC3), and xeroderma pigmentosum complementation group D (XPD) repair genes may lead to genetic instability and leukemogenesis. The purpose of the study was to evaluate the association between XRCC1 Arg399Gln, Arg280His and Arg194Trp, XRCC3 Thr241Met, and XPD Lys751Gln polymorphisms and the risk of developing CML in Romanian patients. A total of 156 patients diagnosed with CML and 180 healthy controls were included in this study. We found no association between CML and XRCC1 or XRCC3 variant genotypes in any of the investigated cases. A significant difference was observed in the variant genotype frequencies of the XPD Lys751Gln polymorphism between the patients with CML and control group (for variant homozygous genotypes, OR = 2.37; 95% CI = 1.20–4.67; P value = 0.016 and for combined heterozygous and variant homozygous genotypes, OR = 1.72; 95% CI = 1.10–2.69; P value = 0.019). This was also observed when analyzing the variant 751Gln allele (OR = 1.54; 95% CI = 1.13–2.11; P value = 0.008). Our results suggest that the XPD Lys751Gln variant genotype increases the risk of CML.

Lack of Association between the 4234G/C X-Ray Repair Cross- Complementing 2 ( XRCC2 ) Gene Polymorphism and the Risk of Endometrial Cancer among Polish Population

“…Among them, polymorphisms of X-ray repair cross complementing group 2 (XRCC2) have been studied extensively [3][4][5].…”

Association between XRCC3 Thr241Met polymorphism and risk of osteosarcoma in a Chinese population

“…However, some studies have shown different results (Xu et al, 2013;Bănescu et al, 2014;Xing et al, 2014;Bashir et al, 2015). Bănescu and colleagues reported that the XRCC3 Thr241Met polymorphism was not associated with the risk of chronic myeloid leukemia (Bănescu et al, 2014).…”

“…Bănescu and colleagues reported that the XRCC3 Thr241Met polymorphism was not associated with the risk of chronic myeloid leukemia (Bănescu et al, 2014). Xu and colleagues revealed that XRCC3 Thr241Met polymorphism was not associated with the development of lung cancer in a meta-analysis (Xu et al, 2014).…”

Farmacogenética, tabaco, alcohol y su efecto sobre el riesgo de desarrollar cáncer

“…Los polimorfismos gené-ticos de las enzimas implicadas en estos procesos de reparación van a determinar su capacidad funcional, pudiendo conducir a una menor capacidad de reparación del ADN, que puede ser la base de una tasa de mutación más alta, y como consecuencia última provocar un aumento de riesgo de desarrollo de procesos tumorales [33][34][35] . Los polimorfismos en ERCC1 y ERCC2 han sido asociados a un mayor riesgo para el desarrollo de cáncer de piel, cáncer de mama y cáncer colorectal [36][37][38][39][40] .…”